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A B S T R A C T
Purpose
Follicular lymphoma (FL) is an indolent cancer, with effective but rarely curative treatment options.
As a standard study end point for first-line FL therapy, progression-free survival (PFS) requires
extended follow-up (median PFS, . 7 years). To provide patients with earlier access to newer
therapies, an earlier end point to expedite clinical trials is needed. Our objective was to formally
assess the complete response rate at 30 months (CR30) after initiation of induction therapy as
a potential surrogate end point for PFS in first-line FL therapy.
Patients and Methods
We analyzed individual patient data from 13 randomized multicenter trials of induction and main-
tenance regimens in first-line FL therapy published after 1990 and with sufficient data to evaluate
whether CR30 could predict treatment effects on PFS. Correlation of the CR30 odds ratio with the
PFS hazard ratio was evaluated by both linear regression (R2WLS) and bivariate copula (R
2
Copula)
models. Prespecified criteria for surrogacy required either R2WLS or R
2
Copula $ 0.80, with a lower-
bound 95% CI . 0.60.
Results
Data from eight induction and five maintenance randomized trials in 3,837 evaluable patients were
analyzed. The prespecified surrogacy thresholdwasmet, with an R2WLS of 0.88 (95%CI, 0.77 to 0.96)
and an R2Copula of 0.86 (95% CI, 0.72 to 1.00). Multiple sensitivity and supplemental analyses
supported the robustness of the findings. A minimum 11% absolute improvement in CR30 from
a 50% control rate predicted a significant treatment effect on PFS (hazard ratio, 0.69).
Conclusion
This large, prospective, pooled analysis of randomized chemotherapy, immunotherapy, and
chemoimmunotherapy trials demonstrates that CR30 is a surrogate end point for PFS in first-line FL
treatment trials. Use of this end point may expedite therapeutic development with the intent of
bringing novel therapies to this patient population years before PFS results are mature.
J Clin Oncol 35:552-560. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Follicular lymphoma is the most common in-
dolent form of non-Hodgkin lymphoma, with an
estimated 16,000 new cases1 occurring annually
in the United States. Although median survival
now exceeds 10 years, follicular lymphoma re-
mains largely incurable, characterized by repeated
remission and recurrence over many years.
New treatment approaches remain a critical
need. Progression-free survival (PFS) is presently
the principal end point for regulatory approval of
new agents. However, advances in treatment
and the indolent nature of follicular lymphoma
challenge the use of PFS as the primary end
point in clinical trials, where median PFS now
approaches 6 to 8 years.2,3 This extended PFS
prolongs trial duration, hinders the efficiency
of meeting regulatory end points, lengthens
exposure to ineffective treatments within trials,
and limits the ability to expeditiously provide
new effective therapeutic options. Therefore,
the identification of alternative (ie, surrogate)
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end points that are measured earlier but can reliably predict
PFS treatment effects is a critical need.
Overall response rate has been considered an end point for
Food and Drug Administration accelerated approval, but it is most
commonly used in late-line treatment settings or in high-risk
populations.4 In follicular lymphoma, complete response re-
quires the disappearance of detectable clinical, biochemical, and
radiographic evidence of disease and disappearance of all disease-
related symptoms. Patients who achieve complete response have
better outcomes than patients who achieve partial response or
stable disease.5-8 Results from randomized studies have sug-
gested that in general, treatments with superior PFS have higher
complete response rates.3,9,10 An observational study showed
that early progression predicted poor outcome,11 and literature-
based meta-analyses have identified a correlation between re-
sponse rate and progression-related end points in indolent non-
Hodgkin lymphoma.12,13 However, as a result of variations in
end point definitions and lack of individual patient data, trial-
level correlation is difficult to interpret, and patient-level
correlation cannot be assessed.
To formally assess complete response rate at a specific time
point as a potential surrogate end point, the Follicular Lymphoma
Analysis of Surrogate Hypothesis (FLASH) group conducted
a prospectively planned pooled analysis of individual patient data




In September 2011, a comprehensive search of publications on
follicular lymphoma in Medline maintained by the US National Library of
Medicine was conducted with the use of the search terms follicular
lymphoma AND randomized, indolent lymphoma AND randomized, and
low-grade lymphoma AND randomized. Multiple cooperative, collabo-
rative, and academic groups from North America and Europe also were
approached for potentially completed and soon-to-be-published studies.
Eligible studies were multicenter randomized trials in patients with pre-
viously untreated follicular lymphoma with a sufficient sample size ($ 100
in total or $ 50 cases of follicular lymphoma) and published after 1990.
Trials that evaluated only induction treatment versus observation and
studies without prespecified imaging, including computed tomography
(CT), were excluded. All trials assessed complete response by using clinical
and CT criteria.
The owners of all identified studies that met the prespecified in-
clusion eligibility criteria were contacted for individual patient data
sharing. For the studies that transferred data, the feasibility of calculating
30-month complete response status was evaluated. Authors who refused
data sharing or who did not provide sufficient data to determine 30-month
complete response status were excluded. All exclusions were based on data
quality and availability only and were determined before statistical analysis
of the end points.
Surrogate End Point Candidates
On the basis of the published data and the balance between
reducing the time required for trial conduct and accurately assessing
the full treatment effect, the complete response rate at 30 months
(CR30) after enrollment (ie, initiation of induction treatment) was
prospectively selected as the principal surrogate candidate. This time
point corresponds to the completion of current standard-of-care
treatment, including 6-month induction and 2-year maintenance
treatment.1,11,14 Unconfirmed complete response was not considered
for the primary analysis; response assessments required CT scan but
not bone marrow evaluation, and investigator determination of
complete response was accepted. The secondary surrogate end point
candidate was complete response rate at 24 months (CR24) to be
evaluated only if the surrogacy of CR30 was established.
The disease assessment measure at exactly 30 months after enroll-
ment was not always available because of variations in specific time points
for response evaluation and recording. When complete response (non-
complete response) status was observed both before and after the 30-month
time point, the end point status could be determined unambiguously.
When response status observed before and after the 30-month time point
differed, the determination of 30-month complete response status re-
quired calculation rules. For these cases, any assessment result within awindow
of 27 to 33 months (inclusive) after enrollment provided complete response
status at 30 months. When no disease was observed within the window,
30-month complete response status could not be determined (ie, missing
values). A predefined cut point of . 20% of patients with missing
complete response status data within a study after calculations resulted in
study exclusion from surrogacy analyses.
Statistical Methods
True end point. The primary clinical end point was PFS, defined as
time from enrollment to first documented disease progression or death as
a result of any cause, whichever occurred first. Living patients without
documented disease progression were censored on the date of last disease
evaluation. Both primary end point and surrogate candidate were derived
according to consistent calculation rules across studies.
General statistical methods. Within-trial treatment effects and 95%
CIs for PFS and complete response end points were quantified through the
hazard ratio (HR) and odds ratio (OR) estimated by the Cox proportional
hazard regression model and logistic model, respectively. A bivariate
Plackett copula model15 was used to estimate the HR for PFS and the OR
for complete response end points when patient-level correlation was es-
timated simultaneously. Analyses were performed with SAS 9.4 (SAS
Institute, Cary, NC) and R version 2.14.0 (The R Project) software.
Surrogacy evaluation. At the trial level, two commonly used surro-
gacy measures were considered: R2Copula
15 and R2WLS
16,17 (which is based
on the weighted least square [WLS] regression method), where R2Copula
takes into account patient-level correlation between the two end points and
R2WLS does not. The predefined rule for declaring trial-level surrogacy
required R2WLS or R
2
Copula $ 0.80 with a lower 95% CI bound . 0.6 and
neither estimate , 0.7. The threshold of 0.8 was defined as a conservative
approach in this setting, wherein precedent is limited.16-18 Supplemental
trial-level surrogacy measures included the surrogate threshold effect19; the
minimum treatment effect on the surrogate required to confidently predict
a significant treatment effect on PFS in a future trial; and concordance of
significance,20 which was defined as the proportion of trials with the same
conclusions for both the surrogate and the true end point (ie, both sig-
nificant or both nonsignificant for treatment effect). At the patient level,
the global OR for comparing PFS status beyond a particular time point
between patients with and without complete response was estimated
through the bivariate Plackett copula model15; patient-level correlation is
a supportive but not a sufficient condition for surrogacy validation.
Sensitivity and Subpopulation Analysis
Leave-one-out cross-validation, which compares the predicted with
the observed log(HR)s on PFS on the basis of the estimated trial-level
model that leaves one trial out at a time, was used to assess the prediction
performance of the regression model. Leave-one-out estimation, which re-
estimated the R2 when one trial was excluded at a time, identified potential
influential trials. Secondary calculation rules (Appendix Fig A1, online
only) to account for the typical course of follicular lymphoma in patients
who underwent first-line treatment provided a sensitivity analysis. Further
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sensitivity analyses were both unconfirmed complete response and
complete response in the calculations. Surrogacy was further exam-
ined within subpopulations defined by treatment type (ie, studies with
and without rituximab), study design (studies that randomly assigned
patients before induction versus before maintenance treatment), and
key patient characteristics (high-risk versus low/intermediate-risk
Follicular Lymphoma International Prognostic Index [FLIPI] score).
RESULTS
Patient Characteristics
Three hundred forty-six references were individually exam-
ined; 29 studies met the required selection criteria (Fig 1). The
owners of these 29 studies were contacted, and 22 provided in-
dividual patient data. Seven were subsequently excluded for lack of
sufficient data to derive 30-month complete response. Two of 15
studies had . 20% missing complete response status after clinical
calculation rules were applied and were subsequently excluded
from further analyses. Therefore, 13 studies (eight induction,
five maintenance) in 3,837 patients were analyzed, with all ex-
clusions solely based on data availability irrespective of the actual
trial 30-month complete response and PFS results. Table 1 lists the
trial-level characteristics of the 13 studies.3,9,21-33 Median patient
age was 56 years (range, 19 to 90 years); 50.3% were male, 57.6%
had Eastern Cooperative Oncology Group performance status of
0 at enrollment, 44.0% had a high FLIPI score, and 67.8% had Ann
Arbor stage IV disease. Overall, the excluded studies were con-
ducted during the same era as the those included, with similar
patient characteristics. Patient treatment assignment was analyzed
according to the intention-to-treat principle. All examined cova-
riates were well balanced between the experimental and the control
arms (Table 2). Median follow-up time among patients without
progressive disease ranged from 30 to 151 months between studies.
Surrogacy Analysis for Principal Surrogate End Point
Candidate (30-Month Complete Response)
Trial-level correlation between CR30 and PFS. Figure 2A shows
the trial-level association between treatment effects on CR30 and
PFS. A strong correlation was observed between the treatment
effects on the two end points at the trial level (R2WLS, 0.88 [95% CI,
0.77 to 0.96]; R2Copula, 0.86 [95% CI, 0.72 to 1.00]), which met
the predefined criteria for surrogacy. Twelve (93.2%) of the 13
trials had concordance of significance. The estimated surrogate
threshold effect was 1.56, which indicated that an observed OR
346* references identified
29 eligible studies (40 references) 
considered and the owners 
contacted
7 studies exclude because unable to share IPD
2 studies excluded because of > 20% of the patients with
missing CR status at 30 months for principal surrogate
end point candidate
7 studies excluded because of insufficient response data:
  3 disease evaluation data ended before 24 months
     after enrollment
  2 no record of the exact date when
     responses were evaluated
  2 response data at each of the evaluation time points
     not available
306 excluded references/did not meet one or more 
inclusion criteria:
  159 other: review/comments
  39 non-randomized studies
  19 studies in relapsed/refractory-only setting
  16 uncertain/insufficient planned data quantity and
    quality for proposed surrogacy analysis
  14 other: biomarker/translational MOA
  12 each small sample size or published before 1990
  8 each other: retrospective/meta-analysis or other
    histology
  6 other: case studies/methodology/other
  5 each non-US/non-EU; other: health
    economics/pharmacoeconomics
  1 each single-center study, study that evaluated
     induction treatment v observation, study with
     radiotherapy as comparator
22 studies provided IPD
15 studies included for
assessing missing percentage of
candidate surrogate end points
13 studies included in surrogacy
evaluation for principal surrogate
end point candidate
Fig 1. Flowchart of study selection. *Three
hundred forty-two references were identified
through the initial September 2011 Medline
database search, and four references were
published after the initial literature search.
CR, complete response; EU, European Union;
IPD, individual patient data;MOA,mechanism
of action.
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$ 1.56 for CR30 would predict a significant treatment effect on
PFS in a future trial, which translates to an absolute improvement
in the CR30 of 11%, assuming a control arm CR30 of 50%.
Patient-level correlation between CR30 and PFS. The global
OR was 11.8 (95% CI, 10.0 to 13.7), which indicates sub-
stantially higher odds of remaining alive and progression free
beyond a particular time point for patients who achieve
complete response at 30 months compared with those who do
not.
Sensitivity analyses. Leave-one-out cross-validation demon-
strated consistency between observed and predicted PFS treatment
effects for each trial on the basis of the CR30 (Fig 2B). To identify
potentially highly influential trials, one trial at a time was excluded to
re-estimate the R2 measures (Appendix Fig A2, online only); none of
the R2 estimates were , 0.8, and none of the lower bounds of the
95% CI were, 0.6. By applying secondary clinical calculation rules,
the surrogacy of CR30 was consistent (R2WLS, 0.88 [95% CI, 0.79 to
0.97]; R2Copula, 0.86 [95% CI, 0.71 to 1.00]). Eight studies recorded
unconfirmed complete response. When including both complete
response and unconfirmed complete response, slightly stronger
trial-level surrogacy was observed for CR30 (R2WLS, 0.96 [95% CI,
0.90 to 1.00]; R2Copula, 0.96 [95% CI, 0.91 to 1.00]).
Subgroup analyses. Subpopulation analyses that separately
examined trials that contained or did not contain rituximab, in-
duction trials, maintenance trials, and patients with high FLIPI
scores showed consistently high levels of surrogacy, with R2 es-
timates from 0.8 to 0.9. However, although patient-level corre-
lation remained strong, among the subset of patients with low-to-
intermediate FLIPI scores, the R2 statistics were moderate (range,
0.5 to 0.6; Table 3).
Surrogacy Evaluation for Secondary Surrogate End Point
Candidate (CR24)
Because CR30 met the predefined criteria, the surrogacy of
CR24 was evaluated. Four studies had. 20% missing data for 24-
month complete response and were excluded. Among the
remaining 11 studies (2,728 patients), patient-level correlation
remained high (global OR, 8.27; 95% CI, 6.82 to 9.71). However,
the strong correlation between treatment effects on CR24 and PFS
was demonstrated only by R2WLS (0.84; 95% CI, 0.63 to 0.95), not
R2Copula (0.67; 95% CI, 0.35 to 0.99). In analyses that excluded one
small outlier study (Fig 2C), both R2WLS (0.86; 95%CI, 0.70 to 0.97)
and R2Copula (0.83; 95% CI, 0.65 to 1.00) demonstrated strong
Table 2. Patient Characteristics on the Basis of 13 Trials Included in the Primary Analysis
Characteristic Control, No. (%)
Experimental,
No. (%) Total, No. (%) P
No. of patients 1,988 1,849 3,837
Age (continuous) .0306*
Mean (SD) 54.92 (11.23) 55.71 (11.33) 55.30 (11.29)
Median 55.67 56.51 56.00
Range 21.00-85.67 18.96-90.10 18.96-90.10
Age (categorical), years .0268†
, 50 620 (31.2) 552 (29.9) 1,172 (30.5)
50-59 668 (33.6) 561 (30.3) 1,229 (32.0)
60-69 507 (25.5) 537 (29.0) 1,044 (27.2)
$ 70 193 (9.7) 199 (10.8) 392 (10.2)
Sex .5590†
Female 979 (49.2) 928 (50.2) 1,907 (49.7)
Male 1,009 (50.8) 921 (49.8) 1,930 (50.3)
ECOG performance status‡ .0972†
Missing 84 115 199
0 1,065 (55.9) 1,030 (59.4) 2,095 (57.6)
1 752 (39.5) 626 (36.1) 1,378 (37.9)
2+ 87 (4.6) 78 (4.5) 165 (4.5)
FLIPI category§ .9323†
Missing 229 250 479
Low (0-1) 311 (17.7) 288 (18.0) 599 (17.8)
Intermediate (2) 677 (38.5) 606 (37.9) 1,283 (38.2)
High (3-5) 771 (43.8) 705 (44.1) 1,476 (44.0)
Ann Arbor stagek .5672†
Missing 1 4 5
I/II 106 (5.3) 93 (5.0) 199 (5.2)
III 522 (26.3) 512 (27.8) 1,034 (27.0)
IV 1,359 (68.4) 1,240 (67.2) 2,599 (67.8)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; SD, standard deviation.
*Unequal variance t test.
†x2 test.
‡ECOG performance status describes a patient’s level of functioning in terms of ability to care for self, daily activity, and physical ability on a scale of 0 (fully active)
to 5 (dead).
§FLIPI is a validated index that is based on five clinical factors (age . 60 years, disease stage III or IV, more than four lymph node groups involved, serum hemoglobin
, 12 g/dL, and serum lactate dehydrogenase greater than the upper limit of normal).39 If present, each factor is assigned 1 point, and the total FLIPI score divides patients
into three levels of risk that are prognostic for overall survival: 0 to 1 points (low risk), 2 points (intermediate risk), and 3 to 5 points (high risk).
kThe Ann Arbor staging system for lymphomas is determined by the location and extent of the disease and ranges from stage I (cancer is located in a single region) to
stage IV (diffuse or disseminated involvement).
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trial-level correlation. Because this exclusion was post hoc, the
results for CR24 are considered hypothesis generating only.
DISCUSSION
This pooled analysis assembled individual patient data from 13
randomized trials in follicular lymphoma initiated worldwide from
1980 to 2007. To our knowledge, this analysis is the first to be based
on integrated individual patient data from randomized controlled
trials in lymphoma. Unlike literature-based meta-analysis, indi-
vidual patient data ensure the consistent calculation of end points
and hence, the consistent interpretation of the within-trial treat-
ment effects across all studies. The analysis demonstrated that
treatment effects on CR30 strongly predict treatment effects on
PFS. The results are highly consistent across various surrogacy
estimationmethods and sensitivity analyses. The strong association
was maintained irrespective of the inclusion of rituximab in the
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Fig 2. (A) Trial-level correlation between complete response rate at 30 months (CR30) after initiation of induction treatment (per primary calculation rules) and
progression-free survival (PFS). Thirteen studies are included. Gold indicates rituximab trials; blue, nonrituximab trials; triangle, induction trial; and circle, main-
tenance trial. The size of the circles and triangles is proportional to the sample size. The fitted weighted least squares regression line (solid line), is log(hazard ratio
[HR]PFS) = 20.093 – 0.636 3 log(odds ratio [OR]CR30). The dashed lines indicate 95% prediction limits. The horizontal dashed line corresponds to the log(HRPFS) of
0 (ie, HR of 1). The vertical dashed line corresponds to the log(ORCR30) of 0 (ie, OR of 1). (B) Assessment of the prediction of log(HRPFS) on the basis of the estimated
regression model at the trial level by leave-one-out cross-validation (CR30 based on primary calculation rules). Gold indicates rituximab trials; blue, nonrituximab
trials; triangle, induction trial; circle, maintenance trial. For each trial, the open circles and triangles are the predicted log(HRPFS) based on the estimated weighted
least squares regression line at the trial level after removing the trial listed; the horizontal bars are the 95% prediction intervals. The solid red circles are the observed
log(HRPFS) of the trial. (C) Trial-level correlation between complete response rate at 24 months (CR24) after initiation of induction treatment and PFS (per primary
calculation rules). Eleven studies are included. Gold indicates rituximab trials; blue, nonrituximab trials; triangle, induction trial; and circle, maintenance trial. The size
of the circles and triangles is proportional to the sample size. The fitted weighted least squares regression line (solid line), is log(HRPFS) = 0.043 – 0.726 3 log
(ORCR24). The dashed lines indicate 95% prediction limits. The horizontal dashed line corresponds to the log(HRPFS) of 0 (ie, HR of 1). The vertical dashed line
corresponds to the log(ORCR24) of 0 (ie, OR of 1).
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regimen or whether the trials involved random assignment at
induction or maintenance. When including both complete re-
sponse and unconfirmed complete response (available in eight
studies), a slightly stronger trial-level surrogacy was observed.
Seven of the 13 included studies began accrual after 1999, and
all used the 1999 National Cancer Institute–sponsored In-
ternational Working Group or similar response criteria.34 All studies
required rigorous response assessment schedules, with clinical and
physical examination and CT imaging.Median duration of complete
response was 41.6months (range, 2.3 to 175.2 months), with 96.2%,
83.8%, and 62.2% of complete responses lasting. 1, 2, and 3 years,
respectively. The end point of CR30 thus represents a durable
treatment-induced complete response, which supports its potential
use as a primary end point in future trials in which the treatment
goal is the achievement and maintenance of complete response.
The relationship between CR30 and PFS was maintained across
all evaluated trials, including induction-only trials, which suggests
that even if standard-of-care treatment changes from a 30-month
total course, the end point will be robust for therapeutic strategies
that seek durable complete response. These findings support CR30
as appropriate for use as a primary study end point in patients with
previously untreated follicular lymphoma, with the intent of bringing
novel therapies to this patient population years before PFS results are
available.
End-of-treatment response assessment may be more accurate
with positron emission tomography (PET)/CT imaging than with
CT imaging alone. Retrospective35 and prospective36 studies have
demonstrated improved PFS prognostication in patients with PET-
negative relative to PET-positive findings at the end of treatment.
PET/CT imaging has been recommended for use in the evaluation
of response in PET-avid lymphoma, including follicular lym-
phoma,37 whereby partial response and unconfirmed complete
response according to International Working Group 1999 criteria34
are classified as complete metabolic response if residual lesions are
PET negative. PET negativity at the end of treatment requires
further investigation as a potential surrogate end point, but because
these criteria are a modification rather than a major redefinition,
we expect that the relationship between CR30 and PFS would
remain with PET evaluation.
Only one of the two primary trial-level surrogacy measures for
CR24 met the predefined qualification criteria. A post hoc analysis
that excluded an outlier study resulted in both trial-level surrogacy
measures showing strong correlation, consistent with a recent
cohort study of patients with follicular lymphoma treated with
chemoimmunotherapy.11 Additional data are required to re-
consider surrogacy of the complete response rate at this assessment
time point. Because CR24 did not meet our prespecified criteria,
no additional end points were considered as a part of our formal
end point validation. Subsequent hypothesis-generating analyses of
additional possible end points derived by using this rich data set are
ongoing. The extended overall survival of patients, which is the
reason that PFS is the current standard end point, precludes
a meaningful assessment of the relationship between CR30 and
overall survival.
Patients’ clinical and disease characteristics affected the es-
timated surrogacy of CR30. A strong correlation existed between
CR30 and PFS among patient groups with high FLIPI scores,
whereas the correlation among patients with low to intermediate
FLIPI scores was less strong. The reduced correlation is likely due
to the prognostic heterogeneity in the low to intermediate FLIPI
groups. Similar findings were observed when CR30 surrogacy was
evaluated on the basis of patients with stage IV disease (n = 2,585;
R2WLS, 0.92 [95% CI, 0.85 to 0.97]; R
2
Copula, 0.94 [95% CI, 0.87 to
1.00]) versus stage I to III disease (n = 1,207; R2WLS, 0.58 [95% CI,
0.25 to 0.87]; R2Copula, 0.59 [95% CI, 0.24 to 0.95]). In ongoing
phase III trials, the majority of patients have stage III or IV disease





Trial-Level Surrogacy Patient-Level Surrogacy
R2WLS (95% CI) R
2
Copula (95% CI) Global OR* (95% CI)
Overall 13 (3,837) 0.88 (0.77 to 0.96) 0.86 (0.72 to 1.00) 11.84 (10.03 to 13.65)
Within subpopulations defined by trials with or without
rituximab
Rituximab trial† 9 (2,851) 0.85 (0.62 to 0.97) 0.80 (0.56 to 1.00) 11.08 (9.13 to 13.03)
Nonrituximab trial 4 (986) 0.91 (0.05 to 1.00) 0.96 (0.90 to 1.00) 14.40 (9.96 to 18.84)
Within subpopulations defined by study type
Induction trial‡ 8 (2,207) 0.89 (0.75 to 0.98) 0.89 (0.74 to 1.00) 10.34 (8.27 to 12.41)
Maintenance trial‡ 5 (1,630) 0.93 (0.84 to 1.00) 0.89 (0.71 to 1.00) 14.14 (10.82 to 17.46)
Within subpopulation defined by FLIPI§
Highk 9 (1,415) 0.87 (0.68 to 0.98) 0.73 (0.42 to 1.00) 14.10 (10.43 to 17.78)
Low to intermediate 10 (1,882) 0.45 (0.02 to 0.93) 0.57 (0.17 to 0.97) 9.00 (7.07 to 10.92)
Abbreviations: Copula, bivariate Plackett copula model; FLIPI, Follicular Lymphoma International Prognostic Index; HR, hazard ratio; OR, odds ratio; WLS, weight least
squares.
*The global OR for progression-free survival status beyond a particular time point that compares responders versus nonresponders was estimated through the bivariate
Plackett copula model. The higher the value, the stronger the association. A lower bound of the 95% CI . 1 indicates a significant association.
†Rituximab trial refers to studies with at least one arm with rituximab.
‡Induction (maintenance) trial refers to studies with random assignment before start of induction (maintenance) treatment.
§FLIPI is a validated index that is based on five clinical factors (age. 60 years, disease stage III or IV, more than four lymph node groups involved, serum hemoglobin,
12 g/dL, and serum lactate dehydrogenase greater than the upper limit of normal).39 If present, each factor is assigned 1 point, and the total FLIPI score divides patients
into three levels of risk that are predictive of overall survival: 0 to 1 points (low risk), 2 points (intermediate risk), and 3 to 5 points (high risk). Cancer and Leukemia Group B
(CALGB) 7951, ERP_165, and Swiss Group for Clinical Cancer Research (SAKK) 35/98 were not included because FLIPI scores were not supplied.
kFurther excluding the FavId06 study because among patients with high FLIPI scores, all were in the experimental arm and classified as having noncomplete response
at 30 months.
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because the treatment approach is similar for both stages. To
inform the use of CR30 as a surrogate end point in future trials, we
estimated trial-level correlation in patients with stage III and IV
disease and identified high correlation (R2WLS, 0.87 [95%CI, 0.75 to
0.97]; R2Copula, 0.91 [95% CI, 0.81 to 1.00]). Because we expect
patients with high risk or high tumor burden to be the main study
population for further first-line follicular lymphoma treatment
trials in which the achievement of durable complete response is
relevant, the consistently strong correlation between CR30 and PFS
observed in the high-risk FLIPI and stage III to IV populations
supports CR30 as a surrogate end point in such trials. Further-
more, the median age of patients included in this analysis is
younger than that of patients with follicular lymphoma in the
general population. This anticipated phenomenon is associated
with clinical trial enrollment and does not preclude the use of
CR30 as a surrogate end point for follicular lymphoma trials, but it
limits the extrapolation of CR30 as a predictor of PFS for patients
treated in general clinical practice.
As with any surrogate end point, the use of CR30 in future
trials must be comprehensively considered in the context of disease
population and treatment type. The findings are based on trials of
chemotherapy with or without rituximab and on treatments that
lasted # 30 months. We recommend CR30 as an appropriate
primary end point for trials that evaluate novel therapies that aim
to maintain and/or increase durable complete response in patients
with previously untreated follicular lymphoma. Future updates
with data from newly maturing trials will be important to ensure
continued applicability of these findings, and trials should con-
tinue to collect robust PFS and overall survival data to fully un-
derstand long-term treatment effects. Other surrogate end point
candidates, such as complete response or PFS status at earlier time
points are to be explored in future studies within the FLASH
collaboration. These findings also demonstrate the value and
potential of international data sharing consortia to address critical
issues that one trial or group cannot address alone.17,38
In conclusion, this pooled analysis of randomized chemo-
therapy, immunotherapy, or chemoimmunotherapy trials dem-
onstrates that complete response at 30 months after initiation of
induction treatment may serve as a surrogate end point for PFS in
first-line follicular lymphoma treatment trials.
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First PD ≤ 30 months
Scenario 1.1
60 months
PD (or death*) observed AND the PD (or death*)
date ≤ 30 months after enrollment
CRu/PR/SDCR non-PD PD
A
CRu/PR/SDCR non-PD PD30m-CR = CR
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First known CR ≤ 30
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Scenario 1.3
60 months
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 If t1gap < 6 months AND t2gap > 12 months (this implies t1gap
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At least one CR observed AND first PD date > 30 months
AND last known CR date < 30 months








CRu/PR/SD ≥ 30 months
Scenario 1.2
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No CR observed AND last known non-PD and non-CR
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No CR observed AND first PD date > 30 months AND last known
non-PD and non-CR date < 30 months




If t1gap < 6 months and t2gap < 6 months, then 30m-CR = closest
   status
If t1gap < 6 months and t2gap > 6 months, then 30m-CR = non-CR












At least one CR observed AND first PD data > 30 months
AND first CR date > 30 months
F
Fig A1. Secondary calculation rules for complete response (CR) rate at 30 months (CR30) after initiation of induction treatment. (A to G) The determination algorithm
(stated in the blue boxes) of 30-month CR status (30m-CR) is illustrated according to various scenarios. CR, complete response; CRu, unconfirmed complete response; PD,
progressive disease; PR, partial response; SD, stable disease; tgap, gap between two time points.
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Fig A2. Re-estimating R2WLS and R
2
Copula by leaving one trial out at a time (complete response rate at 30 months [CR30] based on primary imputation rules). For each
labeled trial, R2WLS and R
2





solid bars are the 95% CIs estimated on the basis of the quantiles of bootstrap samples for R2WLS and R
2
Copula, respectively. Gray and red lines indicate the cutoff points
stated in the surrogacy evaluation criteria for point estimate ($ 0.8) and lower bound of 95%CI (. 0.6), respectively. The numbers sequentially correspond to the following
trials: Cancer and Leukemia Group B (CALGB) 7951, Eastern Cooperative Oncology Group (ECOG) E1496, European Organization for Research and Treatment of Cancer
(EORTC) 20921, Phase III Trial of Favid and Gmcsf [granulocyte-macrophage colony-stimulating factor] vs Placebo and Gmcsf Following Rituximab (FavId06), French Acute
Leukemia and Blood Diseases West-East Group (GOELAMS) 064, M39021, M39023, ML16865, ML17638, Advanced Ovarian Cancer Following Response on Front-Line
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